You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Bulk Pharmaceutical API Sources for BICILLIN C-R 900/300


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for BICILLIN C-R 900/300

Vendor Vendor Homepage Vendor Sku API Url
RR Scientific ⤷  Start Trial R6356983 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for BICILLIN C-R 900/300

Last updated: November 21, 2025

Introduction

BICILLIN C-R 900/300, a widely used long-acting penicillin antibiotic, comprises procaine penicillin G and benzathine penicillin G. Its efficacy in treating various bacterial infections, including syphilis and certain streptococcal infections, depends significantly on the quality and reliable sourcing of its API components. Ensuring an uninterrupted supply of high-quality active pharmaceutical ingredients (APIs) is vital for pharmaceutical manufacturers to meet regulatory standards and maintain product efficacy. This article provides a comprehensive overview of the leading bulk API sources used for BICILLIN C-R 900/300, focusing on global manufacturers, supply chain considerations, and quality assurance protocols.

Composition of BICILLIN C-R 900/300

BICILLIN C-R 900/300 is a combination API formulation consisting of:

  • Procaine Penicillin G (Procaine Benzylpenicillin): Acts as a local anesthetic and prolongs the antibiotic effect.
  • Benzathine Penicillin G (Benzathine Benzylpenicillin): Provides a slow-release mechanism, extending the duration of action.

The active ingredients—both penicillin derivatives—are produced via fermentation processes involving specific bacterial strains, primarily Penicillium species, or through chemical modifications of penicillin bases.

Global API Manufacturing Landscape

The procurement of high-grade APIs for BICILLIN C-R 900/300 involves sourcing from established manufacturers with robust quality control frameworks. Major suppliers span North America, Europe, and Asia, with some manufacturers specializing exclusively in penicillin APIs.

Leading API Producers

1. Novartis / Sandoz

  • Overview: A pioneer in antibiotic API production, Novartis (now Sandoz) has an extensive portfolio of penicillin APIs.
  • Facilities: Located in Europe and North America, with facilities adhering to cGMP standards.
  • API Quality: World-renowned quality assurance, consistent supply, and regulatory compliance.

2. Pfizer Inc.

  • Overview: Pfizer has historically produced penicillin APIs, including benzathine and procaine penicillin derivatives.
  • Supply Capabilities: Global manufacturing hubs with strict quality controls.
  • Market Presence: Supplies APIs across continents to meet global demand.

3. Boehringer Ingelheim

  • Overview: Specializes in beta-lactam antibiotics and related APIs.
  • Strengths: Focus on high purity APIs, innovative fermentation techniques.
  • Regulatory Status: Approved by major regulatory agencies, including the FDA and EMA.

4. Zhejiang Longshin Pharmaceutical Co., Ltd. (China)

  • Overview: An emergent API manufacturer with growing market share.
  • Production Focus: Produces benzathine penicillin G with competitive pricing.
  • Quality Assurance: Certified under ISO standards, meeting WHO prequalification if applicable.

5. Wockhardt Limited (India)

  • Overview: A major global supplier of penicillin APIs, including procaine and benzathine formulations.
  • Facilities: GMP-compliant plants with capacity for large-volume production.
  • Certifications: WHO-GMP, USFDA, EMA approvals enhance credibility.

Emerging and Regional API Suppliers

  • Shanghai Pharmaceuticals (China): Offers cost-effective APIs with a focus on regional markets.
  • KPC Pharmaceuticals (Korea): Known for high-quality beta-lactam APIs.
  • Hikma Pharmaceuticals (UK): Offers APIs and finished formulations.

Supply Chain Considerations

Quality Assurance and Regulatory Compliance

Ensuring API quality involves adherence to stringent standards such as USP, EP, or JP monographs, along with Good Manufacturing Practices (GMP). Suppliers should possess relevant certifications, including WHO-GMP, USFDA approval, or EMA certification, ensuring consistency, purity, and safety.

Supply Stability and Sourcing Risks

Dependence on regional suppliers poses risks linked to geopolitical factors, trade policies, and pandemics. Diversification of sources and reliance on well-established pharmaceutical hubs mitigate supply disruptions.

Pricing and Contractual Agreements

Pricing varies based on manufacturing location, scale, and compliance standards. Long-term contracts with preferred suppliers often include quality benchmarks and supply commitments, ensuring continuity.

Environmental and Ethical Considerations

Regulatory bodies increasingly scrutinize environmental impact, prompting suppliers to adopt sustainable fermentation and waste management practices.

Conclusion

The procurement of bulk APIs for BICILLIN C-R 900/300 involves a strategic selection of reputable manufacturers committed to quality, supply reliability, and regulatory compliance. Key suppliers include industry giants such as Novartis (Sandoz), Pfizer, and Boehringer Ingelheim, complemented by regional producers in China, India, and Korea. Ongoing quality assurance, diversification, and adherence to regulatory standards underpin the integrity of the supply chain, ensuring the consistent production of effective BICILLIN C-R 900/300 formulations.

Key Takeaways

  • Reliable sourcing of procaine and benzathine penicillin G APIs is critical for maintaining the efficacy of BICILLIN C-R 900/300.
  • Leading global suppliers include Novartis/Sandoz, Pfizer, Boehringer Ingelheim, with emerging manufacturers in China and India.
  • Ensuring API quality involves strict adherence to GMP, regulatory approvals, and comprehensive quality assurance protocols.
  • Diversification of sourcing and supplier vetting mitigate risks associated with geopolitical, environmental, and logistical factors.
  • Continuous monitoring of regulatory standards and environmental practices enhances API sourcing integrity.

FAQs

1. What are the primary manufacturers of benzathine penicillin G API?
Major manufacturers include Novartis (Sandoz), Pfizer, Boehringer Ingelheim, Zhejiang Longshin Pharmaceutical, and Wockhardt Limited, all supporting the global supply of benzathine penicillin G.

2. How does API quality impact the efficacy of BICILLIN C-R 900/300?
High-quality APIs ensure proper potency, sterility, and purity, directly influencing treatment effectiveness and patient safety.

3. Are there regions with more reliable API supplies for penicillin derivatives?
Yes, North America and certain European countries maintain highly regulated production standards, though Asian manufacturers like India and China have increased capacity and regulatory oversight, making them viable options.

4. What risks are associated with API sourcing for BICILLIN C-R 900/300?
Risks include supply disruptions, substandard quality, regulatory hurdles, and geopolitical tensions affecting trade logistics.

5. How can manufacturers ensure API supply chain resilience?
By diversifying suppliers, verifying regulatory compliance, establishing long-term contracts, and conducting regular audits, manufacturers can mitigate supply chain risks.


References
[1] World Health Organization. Prequalification of Medicines Programme. Penicillin API Manufacturing Standards, 2022.
[2] European Medicines Agency. Pharmacovigilance and API regulation.
[3] Novartis Annual Report, 2022.
[4] Pfizer Annual Report, 2022.
[5] Boehringer Ingelheim Official Website, API manufacturing overview.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.